Published in Free Radic Biol Med on April 19, 2013
Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med (2015) 0.95
Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence? Front Neurosci (2015) 0.92
Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol (2014) 0.90
Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. Pharmacol Rev (2014) 0.87
Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. Neuropathol Appl Neurobiol (2015) 0.85
Nuclear receptors in neurodegenerative diseases. Neurobiol Dis (2014) 0.85
Metabolic disturbances in diseases with neurological involvement. Aging Dis (2013) 0.84
Aerobic interval training attenuates mitochondrial dysfunction in rats post-myocardial infarction: roles of mitochondrial network dynamics. Int J Mol Sci (2014) 0.80
Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord (2014) 0.80
Protective Effects of Salidroside on Mitochondrial Functions against Exertional Heat Stroke-Induced Organ Damage in the Rat. Evid Based Complement Alternat Med (2015) 0.79
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system. Biochim Biophys Acta (2016) 0.76
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci Rep (2016) 0.76
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders. Neurochem Res (2016) 0.75
Low Cytochrome Oxidase 1 Links Mitochondrial Dysfunction to Atherosclerosis in Mice and Pigs. PLoS One (2017) 0.75
Protective Effects of Aqueous Extract of Luehea divaricata against Behavioral and Oxidative Changes Induced by 3-Nitropropionic Acid in Rats. Evid Based Complement Alternat Med (2015) 0.75
Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Hum Mol Genet (2016) 0.75
Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samples. Metabolomics (2016) 0.75
Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease. Elife (2016) 0.75
mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease. Cell Mol Neurobiol (2014) 0.75
Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. Front Mol Neurosci (2017) 0.75
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell (1998) 18.32
Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature (2002) 14.37
Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J (2008) 12.89
Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab (2005) 11.66
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell (2006) 10.18
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev (2003) 9.93
TFEB links autophagy to lysosomal biogenesis. Science (2011) 8.87
Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell (2004) 8.58
Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev (2004) 6.98
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev (2006) 6.68
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab (2008) 6.22
Roles of PPARs in health and disease. Nature (2000) 5.87
PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol (2005) 5.80
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell (2012) 5.71
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell (2004) 5.67
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell (2006) 5.58
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab (2010) 4.97
Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J Biol Chem (2007) 4.58
Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J (2006) 4.43
Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci (2010) 4.22
Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell (2010) 4.19
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15
Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem (2003) 4.12
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci U S A (2011) 3.49
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab (2006) 3.38
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron (1995) 3.08
OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature (2007) 3.03
PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ (2006) 2.88
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron (2010) 2.54
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet (2011) 2.34
In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab (2011) 2.33
Vesicular glycolysis provides on-board energy for fast axonal transport. Cell (2013) 2.33
Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet (2004) 2.31
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci (1993) 2.27
Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep (2011) 2.20
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med (2011) 2.17
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med (2012) 2.07
The interplay between mitochondrial dynamics and mitophagy. Antioxid Redox Signal (2011) 2.05
Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J (2008) 2.03
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet (2005) 1.96
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med (2010) 1.91
Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol (2010) 1.91
Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol (2009) 1.88
Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med (1999) 1.86
Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp Neurol (1998) 1.85
Requirement for superoxide in excitotoxic cell death. Neuron (1996) 1.80
Oxidative stress in Huntington's disease. Brain Pathol (1999) 1.80
The energetics of Huntington's disease. Neurochem Res (2004) 1.79
Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal (2006) 1.79
Mitofusin 2 protects cerebellar granule neurons against injury-induced cell death. J Biol Chem (2007) 1.73
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med (2010) 1.72
Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage (2009) 1.72
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res (2007) 1.63
Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol (1999) 1.63
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci (2008) 1.59
Energy deficit in Huntington disease: why it matters. J Clin Invest (2011) 1.51
Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci (1995) 1.50
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res (1999) 1.50
Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet (2011) 1.48
Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem (2001) 1.45
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet (2011) 1.44
Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol (2001) 1.44
Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res (2005) 1.43
Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress. Aging (Albany NY) (2011) 1.40
Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev (2009) 1.37
Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther (2006) 1.36
Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem (2004) 1.35
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther (2012) 1.33
The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci (2008) 1.32
Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem (2005) 1.31
Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med (2008) 1.27
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med (2010) 1.27
Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics (2005) 1.25
Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum Mol Genet (2012) 1.25
In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology (2004) 1.24
The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener (2009) 1.23
PGC-1alpha as modifier of onset age in Huntington disease. Mol Neurodegener (2009) 1.22
Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem (2007) 1.21
Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp Neurol (1974) 1.18
Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet (2011) 1.17
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet (2010) 1.14
Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst) (2008) 1.14
Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep (2012) 1.12
Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci (2008) 1.12
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem (2007) 1.11
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet (2002) 6.02
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A (2008) 4.97
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Parkinson's disease. Hum Mol Genet (2007) 3.84
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol (2008) 3.35
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A (2004) 2.77
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem (2002) 2.68
Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2005) 2.58
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci (2002) 2.01
Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med (2010) 1.91
Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol (2010) 1.91
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
The energetics of Huntington's disease. Neurochem Res (2004) 1.79
Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci (2005) 1.79
Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal (2006) 1.79
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int (2008) 1.76
High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet (2002) 1.75
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord (2005) 1.62
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A (2007) 1.58
Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med (2010) 1.57
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci (2004) 1.54
The role of mitochondria in inherited neurodegenerative diseases. J Neurochem (2006) 1.53
Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology (2003) 1.50
Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48
Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol (2005) 1.46
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2005) 1.46
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve (2007) 1.45
Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J (2010) 1.44
Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci (2005) 1.44
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet (2011) 1.44
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem (2005) 1.44
Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev (2005) 1.43
Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem (2002) 1.42
PGC-1alpha, a new therapeutic target in Huntington's disease? Cell (2006) 1.42
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging (2004) 1.37
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci (2009) 1.36
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging (2004) 1.36
Alzheimer's APP mangles mitochondria. Nat Med (2006) 1.36
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta (2009) 1.33
Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther (2012) 1.33
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res (2003) 1.32
The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid Redox Signal (2009) 1.31
Metabolomic analysis and signatures in motor neuron disease. Metabolomics (2005) 1.31
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci (2010) 1.30
PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One (2009) 1.30
Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis (2005) 1.30
Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One (2009) 1.29
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med (2010) 1.27
Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem (2006) 1.26
Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol (2005) 1.25
Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging (2008) 1.24
The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Mol Neurobiol (2005) 1.23
Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis (2005) 1.23
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem (2009) 1.22
A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J (2006) 1.22
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem (2003) 1.20
Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal (2009) 1.20
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med (2004) 1.19
Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One (2009) 1.19
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J Neurochem (2004) 1.19
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem (2004) 1.17
Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet (2006) 1.16
MicroRNA-related cofilin abnormality in Alzheimer's disease. PLoS One (2010) 1.15
Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis (2006) 1.15
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet (2010) 1.14
Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol (2002) 1.13
Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int (2003) 1.13
Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med (2011) 1.13
Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res (2003) 1.13
Nitration of Hsp90 induces cell death. Proc Natl Acad Sci U S A (2013) 1.13
A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Hum Mol Genet (2013) 1.13
NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal (2012) 1.12